Apotex shares begin trading strongly on the Toronto Stock Exchange following its billion-dollar initial public offering. Multiple reports describe a large first-day gain, with the stock opening roughly 17% above the IPO price. Other coverage puts the increase at about 12% in the debut, reflecting early trading fluctuations in the opening minutes. The company’s strong start is widely attributed to investor demand at and immediately after the offering price. With the IPO positioning Apotex as a major new listing, the debut is characterized as one of the more notable TSX introductions since 2021, based on the scale of the offering and how the shares perform at the start of trading. All accounts present the same core development: Apotex’s publicly traded shares open higher than the IPO price and move up further during the early session, signaling solid market reception. The reports focus on the initial share-price movement and provide limited additional details about broader trading performance or long-term expectations.